Recent Updates — DYN
On September 29, 2026, Dyne Therapeutics announced additional one-year clinical data from the multiple ascending dose portion of its Phase 1/2 ACHIEVE trial evaluating zeleciment basivarsen for myotonic dystrophy type 1. The pooled dose group (N=25-26) demonstrated sustained functional improvement across multiple measures, including a 3.2-second decrease in video hand-opening time at six months and significant gains in muscle strength and patient-reported outcomes at twelve months compared to baseline and natural history cohorts. Safety data through April 2026 showed a favorable profile with no related serious adverse events. The company expects topline data from the registrational expansion cohort in Q1 2027, supporting a potential U.S. Accelerated Approval BLA submission in Q3 2027. Dyne Therapeutics operates in the biotechnology industry and develops therapeutics for genetically driven neuromuscular diseases.
Dyne Therapeutics reported a net loss of $178.6 million, or $1.08 per share, for the quarter ended June 30, 2026, compared to a $110.9 million loss in the prior year period. The company completed an underwritten public offering of 21,045,000 shares at $20.50 per share in July 2026, generating approximately $431 million in gross proceeds and $405 million in net proceeds. Cash, cash equivalents, and marketable securities stood at $898.5 million as of June 30, 2026, with expected runway into Q2 2028. Key regulatory milestones include FDA acceptance of the BLA for z-rostudirsen for exon 51 DMD with a PDUFA date of January 21, 2027, and Priority Review granted. The company also completed enrollment in the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1 and received FDA clearance for an IND for DYNE-302 in FSHD. Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for genetically driven neuromuscular diseases.
Dyne Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share. The offering is expected to close on or about July 23, 2026, and is expected to yield net proceeds of approximately $352.1 million. Dyne Therapeutics is a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
Dyne Therapeutics, Inc. announced that the FDA has accepted for review its biologics license application (BLA) for zeleciment rostudirsen (DYNE-251) to treat Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The FDA has granted Priority Review with a target action date of January 21, 2027, and the company expects a potential U.S. launch in Q1 2027. Dyne Therapeutics, Inc. is a biotechnology company developing therapeutic solutions for neuromuscular diseases.
Dyne Therapeutics, Inc. entered into a Second Amendment to its Loan and Security Agreement with Hercules Capital, Inc. and other lenders on June 16, 2026, expanding its debt facility to an aggregate of up to $400.0 million. The amendment added two $50.0 million tranches and increased a final tranche by $25.0 million, while also reducing the minimum cash covenant from 60% to 40% of outstanding obligations. The company borrowed $50.0 million on the closing date, bringing its outstanding principal to $200.0 million. Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuromuscular diseases.